Wuxi STA Pharmaceutical Co., Ltd.

Overview

Wuxi STA Pharmaceutical Co., Ltd. is a subsidiary of WuXi AppTec. It is a global small molecule and polymer active pharmaceutical ingredient (API) and advanced intermediate platform, driving cutting-edge medicinal chemistry from initial discovery to commercial manufacturing.

Therapeutic areas

API / Drug Master Files

Wuxi STA Pharmaceutical Co., Ltd. holds 17 active (24 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• RIVASTIGMINE TARTRATEActive2025-04-01
• MYCOPHENOLATE SODIUMActive2024-06-25
• TACROLIMUSActive2024-06-25
• RIFAPENTINEActive2024-03-28
• CANTHARIDINActive2023-04-14
• DOXERCALCIFEROLActive2022-06-20
• 10-DEACETYLBACCATIN IIIActive2021-03-28
• MITOMYCINActive2020-09-14
• MYCOPHENOLATE MOFETILActive2019-08-02
• GADOPENTETATE DIMEGLUMINEActive2012-11-08
• EPTIFIBATIDEActive2012-09-12
• RISPERIDONEActive2011-12-19
• ESCITALOPRAM OXALATEActive2011-11-21
• CITALOPRAM HYDROBROMIDEActive2010-07-19
• CLOZAPINEActive2006-10-02

Showing 15 of 24 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Wuxi STA Pharmaceutical Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.